HER2-POSITIVE BREAST CANCER

This study tests a drug called trastuzumab-deruxtecan (T-DXd) in people with HER2-positive breast cancer that has spread to 1-3 distant spots (oligo-metastatic). The goal is to shrink or eliminate all cancer with a year of treatment, including local therapies like surgery or radi…

This early-stage trial is testing a vaccine designed to help the immune system recognize and attack HER2-positive breast cancer cells. The vaccine contains two small pieces of the HER2 protein, similar to existing drugs, to trigger an immune response. The study will enroll 36 adu…

This study tests a new drug, CAN016, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, and second, seeing if the drug shrinks tumors. About 90 participants will receive CAN016 every three wee…

This phase 3 trial tests whether a new drug called GQ1005 works better than the current standard treatment T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. Participants have already been treated with trastuzumab and a taxane. The …

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This study tests a new drug, trastuzumab rezetecan, for people with HER2-positive early breast cancer whose tumors don't shrink enough after two cycles of standard therapy. About 124 participants will first receive standard treatment, and those with a poor response will switch to…

This study tests a new drug, RO7771950, designed to reach the brain, for people with HER2-positive breast cancer that has spread to the brain or other organs. About 650 participants will receive either the new drug or an existing drug (tucatinib), both combined with standard ther…

This study tests whether a combination of targeted drugs (pyrotinib and trastuzumab) plus chemotherapy can completely eliminate HER2-positive breast cancer before surgery. About 182 women with early-stage disease will receive 8 cycles of treatment. The main goal is to see if no c…

This phase 3 trial tests an immunotherapy called GLSI-100 in 750 people with HER2-positive breast cancer who are at high risk of their cancer returning after standard treatment. Participants receive a series of injections over a year to help their immune system target and destroy…

This early-stage trial tests a new drug called IAM1363 in adults with advanced cancers that have HER2 alterations, including breast, lung, and stomach cancers that have spread to the brain. The study aims to find the safest dose and see if the drug can shrink tumors. About 383 pa…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This phase 3 trial tests whether a new drug, BL-M07D1, combined with pertuzumab works better than the current standard treatment (docetaxel, trastuzumab, and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. About 596 women aged 18-75 who have …

This pilot study tests whether focused ultrasound, combined with tiny gas bubbles (microbubbles), can help chemotherapy drugs penetrate deeper into HER2-positive breast tumors. Twenty women will receive the ultrasound treatment alongside standard neoadjuvant therapy before surger…

This phase 2 trial is testing a drug called zanidatamab in 20 people with early-stage, low-risk HER2-positive breast cancer. The drug is given intravenously, along with hormone therapy pills (letrozole or tamoxifen). The main goal is to see if the cancer disappears completely by …

This Phase 2 trial at Fudan University tests several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see which combinations best eliminate all signs of cancer (pathological complete response) based on each tumor's specific subtype. Ab…

This phase 2 trial tests a personalized approach for people with HER2+ metastatic breast cancer. Doctors use ctDNA blood tests and imaging to decide when to step up or down treatments, including targeted drugs and local therapies, to achieve long-term remission. The goal is to se…

This study tests whether adding surgery and targeted radiation to standard treatment helps people with HER2-positive breast cancer that has spread to up to 5 spots in the body. About 178 adults will be randomly assigned to receive either standard care alone or standard care plus …

This study tests IKS014, a drug designed to seek out and destroy HER2-positive cancer cells, in people with advanced solid tumors like breast, stomach, and gastroesophageal cancers. The main goals are to find the safest dose and check for early signs of tumor shrinkage. About 165…

This phase 2 trial is testing two standard chemotherapy combinations given before surgery for people with HER2-positive early breast cancer. One group gets docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP); the other gets the same without carboplatin (THP). The main goal…

This study tests whether taking an oral chemotherapy (paclitaxel) along with a fixed-dose injection of two targeted drugs (pertuzumab and trastuzumab) can eliminate all signs of HER2-positive breast cancer before surgery. About 112 adults with early-stage HER2+ breast cancer will…

This study tests whether adding zanidatamab to standard chemotherapy can completely eliminate cancer in people with early-stage HER2-positive breast cancer before they have surgery. About 125 participants with stage II or III disease will receive the combination, and doctors will…

This phase 2 trial is testing two different drug combinations for people with stage I HER2-positive breast cancer after surgery. One group gets trastuzumab emtansine (T-DM1) followed by trastuzumab injections, while the other gets paclitaxel plus trastuzumab. The goal is to see w…

This phase 2 trial is testing whether giving a combination of three drugs—neratinib, an aromatase inhibitor (letrozole or anastrozole), and trastuzumab—before surgery can completely eliminate invasive breast cancer in postmenopausal women with ER-positive, HER2-positive breast ca…

This early-stage study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants will take pa…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target multiple proteins on breast cancer cells. It is for people with advanced or metastatic breast cancer, including HER2-positive and triple-negative types, who have not responded to s…

This phase 3 trial compares a new drug called TQB2102 against a standard chemotherapy combination (TCbHP) for people with HER2-positive breast cancer. The goal is to see if TQB2102 works better at eliminating cancer before surgery. About 544 participants will be randomly assigned…

This study tests whether a new drug combination (pyrotinib + trastuzumab + docetaxel) works better than the standard combo (pertuzumab + trastuzumab + docetaxel) for shrinking early-stage HER2-positive breast tumors before surgery. Researchers will use a blood test to measure tum…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) to fight advanced breast cancer, including HER2-positive and triple-negative types. About 60 adults whose cancer has not responded to standard treatments will receive cells tailored to their t…

This early-phase trial is testing a new way to give the cancer drug T-DXd (Enhertu) — as a shot under the skin instead of an IV drip. The study will enroll 76 adults with metastatic solid tumors to find the safest dose and see how well the body handles it. Researchers will also c…

This study tests whether adding a personalized dendritic cell vaccine to standard chemotherapy and targeted therapy can help people with HER2-positive breast cancer. About 53 participants will receive the vaccine alongside standard drugs before surgery. The main goal is to see if…

This phase 3 study tests a new drug called IBI354, given alone or with another drug (pertuzumab), against the current standard treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The trial aims to see if the new combination can delay …

This study is for people with HER2+ breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease). It combines targeted drugs (tucatinib, trastuzumab, capecitabine) with radiation to the brain or spine. The goal is to see if this approach helps…

This phase 2 trial is testing a combination of anti-HER2 drugs (trastuzumab emtansine, pertuzumab, and docetaxel) plus hormone therapy (tamoxifen or letrozole) given before and after surgery in 74 Nigerian women with HER2-positive breast cancer. The main goal is to see if the can…

This study is tracking 300 people with HER2-positive or HER2-low breast cancer who are receiving trastuzumab-rezetecan as part of their routine care. Researchers are monitoring side effects and how well the drug works in real-world conditions, not in a strict lab setting. The goa…

This Phase I trial is testing a new drug called BL-M17D1 in 20 people with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it shrinks tumo…

This phase 3 trial tests whether a new drug, BL-M07D1, works better than the current standard (T-DM1) for people with HER2-positive breast cancer that still has invasive cancer after initial chemotherapy. About 1,450 women aged 18-75 will be randomly assigned to one of the two tr…

This study is tracking 800 Chinese patients with advanced HER2-positive or HER2-low breast cancer who are receiving trastuzumab deruxtecan (T-DXd) in real-world clinics. Researchers want to see how long patients stay on treatment and how well it works outside of clinical trials. …

This study tests if the heart drug nebivolol can protect the hearts of women with HER2-positive breast cancer who are receiving trastuzumab, a treatment that can weaken the heart. Researchers will measure heart function and quality of life in 56 participants over several months. …

This early-phase trial is testing a radioactive drug called 177Lu-CTR-FAPI in 4 people with advanced pancreatic cancer that has not responded to standard treatments. The drug is given intravenously every 6 weeks for up to 4 doses. Researchers are checking for safety, how much rad…

This study tests a new drug called BL-M07D1, given alone or with pertuzumab, against the standard treatment (taxane + trastuzumab and pertuzumab) for HER2-positive breast cancer before surgery. About 120 women with stage II-III breast cancer will participate. The goal is to see i…

This study tests whether a combination of three drugs—disitamab vedotin, pertuzumab, and toripalimab—can shrink or eliminate HER2-positive breast tumors before surgery. About 40 adults with early-stage breast cancer will receive the drugs intravenously for 18 weeks, then have sur…

This Phase 3 trial tests whether a combination of trastuzumab and neratinib works better than the standard trastuzumab and pertuzumab for women with a certain type of breast cancer (HER2-positive, hormone receptor-positive) who still have small amounts of cancer after initial che…

This early-phase trial is testing a new drug called BL-M07D1 in people with advanced HER2-positive or low-expression breast cancer and other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then testing that…

This phase II trial is testing whether combining two drugs—trastuzumab deruxtecan (Enhertu) and durvalumab—given before surgery can eliminate cancer in people with stage III inflammatory breast cancer that has HER2 protein. The study will enroll 63 participants and measure how ma…

This phase 2 trial is testing whether women with HER2-positive or triple-negative breast cancer who have a complete response to chemotherapy can safely skip surgery or radiation. The study will enroll 152 women and monitor them for cancer recurrence, distant spread, or death. The…

This study tests whether adding the drug pyrotinib to standard trastuzumab therapy can lower the risk of cancer coming back in women with HER2-positive breast cancer who still have cancer cells after initial treatment. About 316 women will take pyrotinib daily for a year. Researc…

This phase 2 trial compares the experimental drug trastuzumab deruxtecan (T-DXd) to standard chemotherapy given before surgery for HER2-positive breast cancer. About 370 participants will receive either T-DXd or standard treatment for three cycles, then further treatment is chose…

This study is testing whether routine brain MRIs can find brain metastases in stage IV breast cancer patients who have no neurological symptoms. Researchers will scan 170 participants at the start and again at 6 months or when their cancer first progresses. The goal is to see how…

This early-phase study tests a radioactive tracer called [68Ga]Ga-ABY-025 for PET scans in 30 adults with advanced HER2-positive cancers (breast, gastric, head/neck, esophageal). Participants receive the tracer and a PET/CT scan before or during standard HER2-targeted therapy. Th…

This study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…

This study is testing whether a special test called HER2DX can help doctors choose the best treatment for people with early-stage HER2-positive breast cancer. About 304 participants will be split into two groups: one group gets standard treatment without the test results, and the…

This study tests a new imaging system that uses light to monitor how breast cancer responds to chemotherapy before surgery. Researchers want to see if it can accurately predict when the cancer is completely gone. The study involves 15 women with specific types of breast cancer. I…

This early-phase study aims to see if a special PET scan using 89Zr-trastuzumab can predict how well HER2-positive breast cancer patients will respond to targeted therapy. Ten newly diagnosed adults will receive the imaging agent and undergo PET/MRI scans. The goal is to improve …

This study compares a special contrast-enhanced mammogram (CEDM+CEDBT) with standard breast MRI to see if it can accurately predict whether breast cancer has been eliminated by chemotherapy. About 30 women with locally advanced breast cancer will get 1-2 of these mammograms durin…

This study is testing whether a special whole-body MRI scan can find breast cancer that has come back or spread to other parts of the body earlier than standard methods. Researchers will follow 145 women with aggressive breast cancer types (HER2+ or triple-negative) for five year…

This study is looking at whether a brain MRI can spot cancer that has spread to the brain in people with certain types of breast cancer (triple negative or HER2-positive, stage IIb or III) who have no symptoms. About 100 participants will get a contrast-enhanced brain MRI, give a…

This study tests whether a special exercise program, called PRESIONA, can prevent nerve damage (peripheral neuropathy) caused by chemotherapy in breast cancer patients. The program combines aerobic and strength exercises with blood flow restriction cuffs. Researchers will compare…

This study tests whether taking probiotics can prevent severe diarrhea in women with HER2-positive breast cancer who are treated with neratinib. About 308 participants will be randomly assigned to receive either probiotics or a placebo for six weeks, alongside standard diarrhea p…

This study looks at whether breast cancer patients on HER2-targeted therapy can safely have fewer heart tests. Currently, patients get heart scans every three months, but most don't change treatment. Researchers will test a personalized schedule based on heart risk, comparing it …

This study is testing whether a special PET/MRI scan using an investigational tracer called [18F]FMISO can help monitor how well chemotherapy works in people with HER2-positive breast cancer. The study involves 25 patients and is for imaging purposes only—it will not change their…

This pilot study tests whether a personalized approach to heart imaging can safely reduce the number of echocardiograms women with early-stage breast cancer need during HER2-targeted therapy. The goal is to avoid unnecessary tests while still catching any heart side effects early…

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…

This study aims to find genetic markers that may explain why some HER2-positive breast cancer patients respond well to treatment while others do not, or experience side effects. Researchers will collect blood samples from 9,000 participants and follow them for five years. The goa…

This study takes a small skin sample from breast cancer patients who have received certain chemotherapies. Researchers will turn those skin cells into heart cells in a lab to study why some patients develop heart problems. The goal is to learn more about the link between treatmen…

This study reviews medical records of 600 people with HER2+ or triple-negative breast cancer who had chemotherapy and still had cancer in their lymph nodes. The goal is to see if skipping additional lymph node removal (axillary dissection) leads to more cancer coming back in the …

This study is testing new drug combinations for breast cancer to see which ones work best for different tumor types. It involves up to 5,000 people with early-stage or locally advanced breast cancer. Researchers use MRI scans and tissue samples before surgery to predict treatment…

This study examines tumor samples from 10 people with HER2-positive breast cancer who still had cancer after standard chemotherapy and trastuzumab. Researchers compare tissue taken before and after treatment to identify markers of resistance. No new treatments are given; the goal…

This study looks at whether educational videos and role-play exercises can help breast cancer patients and their doctors better recognize and manage side effects from certain targeted therapies (antibody drug conjugates). The study involves 30 patients and their clinicians. Resea…

This study is for people with high-risk early breast cancer, including inflammatory breast cancer. Researchers want to see if clusters of tumor cells found in the blood can help predict how well treatment works and the chances of survival. About 130 participants will give blood s…

This study is collecting tumor samples from 1,050 people with early or metastatic breast cancer to analyze fat storage and organelle properties in cancer cells. Researchers aim to create a detailed atlas of these features across different breast cancer subtypes. The goal is to be…

This study is for people with solid tumors that have spread to the brain. Researchers want to collect medical information and samples (like blood and spinal fluid) to better understand why and how brain metastases happen. The goal is to find new ways to treat or prevent them in t…

This study will look at medical records of 60 Russian patients with advanced HER2-positive breast cancer who have received trastuzumab deruxtecan. Researchers want to see how long the drug keeps cancer from growing and how safe it is. The goal is to understand how well this treat…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help predict how well breast cancer responds to chemotherapy given before surgery. Researchers will take blood samples from 125 women with stage II or III breast cancer before, during, and after treat…